Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.50 |
| ▸ | METAP2 | P50579 | 3/20 | 0.47 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17422906 | 0.82 | AHR (0.47) | AHRMETAP2NOS1DYRK1ACYP2A6 | |
| SCHEMBL17433431 | 0.81 | ITK (0.51) | AHRMETAP2NOS1DYRK1ACYP2A6 | |
| SCHEMBL21812417 | 0.81 | CYP19A1 (0.55) | AHRMETAP2NOS1DYRK1ACYP2A6 | |
| SCHEMBL475358 | 0.77 | LMNA (0.52) | AHRMETAP2NOS1DYRK1ACYP2A6 | |
| SCHEMBL22310730 | 0.77 | AOC3 (0.54) | AHRMETAP2NOS1DYRK1ACYP2A6 | |
| SCHEMBL30697897 | 0.77 | LMNA (0.52) | AHRMETAP2NOS1DYRK1ACYP2A6 | |
| SCHEMBL2490392 | 0.77 | AHR (0.47) | AHRMETAP2NOS1DYRK1ACYP2A6 | |
| SCHEMBL20338421 | 0.77 | DAO (0.52) | AHRMETAP2CYP2A6ITKKDM4E | |
| SCHEMBL17422847 | 0.77 | AHR (0.47) | AHRMETAP2NOS1DYRK1ACYP2A6 | |
| SCHEMBL27975970 | 0.77 | DAO (0.52) | AHRNOS1DYRK1ANR4A2HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121601-B1 | NOVEL INDOLE DERIVATIVES, METHODS FOR PREPARING SAME, AND USE THEREOF PARTICULARLY AS ANTIBACTERIAL AGENTS | Université Joseph Fourier (FR) | 2016-06-15 | — | — | EP | disclosed |
| CN-101652346-B | Indole derivatives, process for their preparation and their use, especially as antibacterial agents | UNIV JOSEPH FOURIER | 2013-10-30 | — | — | CN | disclosed |
| US-8343964-B2 | Indolic derivatives, their preparation processes and their uses in particular as antibacterials | UNIVERSITE JOSEPH FOURIER (FR) | 2013-01-01 | — | — | US | disclosed |
| US-20100144726-A1 | NOVEL INDOLIC DERIVATIVES, THEIR PREPARATION PROCESSES AND THEIR USES IN PARTICULAR AS ANTIBACTERIALS | UNIVERSITE JOSEPH FOURIER (FR) | 2010-06-10 | — | — | US | disclosed |
| EP-2121601-A2 | NOVEL INDOLE DERIVATIVES, METHODS FOR PREPARING SAME, AND USE THEREOF PARTICULARLY AS ANTIBACTERIAL AGENTS | Université Joseph Fourier (FR) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008110690-A2 | NOVEL INDOLE DERIVATIVES, METHODS FOR PREPARING SAME, AND USE THEREOF PARTICULARLY AS ANTIBACTERIAL AGENTS | UNIVERSITE JOSEPH FOURIER (FR) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144726-A1 | NOVEL INDOLIC DERIVATIVES, THEIR PREPARATION PROCESSES AND THEIR USES IN PARTICULAR AS ANTIBACTERIALS | GPBAR1, TPH1, GPER1 | AHR 354/4885METAP2 3170/4885NOS1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.